Abstract
Absolute lymphocyte count (ALC) ≥1000 cells/mm3 on day +23 was an independent predictor of prolonged survival in patients with T/NK-cell lymphoma after autologous peripheral blood stem cell transplantation (APBSCT). To understand the prognostic value of lymphocyte recovery, we performed a retrospective study analyzing the result of 59 patients with multiple myeloma (MM) patients who underwent APBSCT. All patients were in complete or partial response after APBSCT. A median age at APBSCT was 51. Peripheral blood stem cells were mobilized and collected after cytoxan and G-CSF. The conditioning regimen was melphalan 200. ALC recovery day was defined as a first day of 3 consecutive days when ALC has been recovered more than 1000/mm3. A median value was used for the analysis of each noncategorical variable. A median follow-up time after APBSCT was 33.8 months and median recovery days of ALC ≥1000 cells/mm3 was 23 days. Prognostic factors at the time of APBSCT for transplant OS and PFS included beta-2 microglobulin, serum albumin, recovery days of neutrophil ≥500/mm3, infused mononuclear cell dose, infused CD+34 cell dose and recovery days of ALC ≥1000 cells/mm3. Univariate analysis revealed that significant variables at APBSCT for overall survival (OS) were beta-2 microglobulin, day of neutrophil engraftment and recovery days of ALC. Positive predictors at APBSCT for progression-free survival (PFS) were beta-2 microglobulin, day of neutrophil engraftment, serum albumin, infused mononuclear cell count, infused CD +34 cell count and recovery days of ALC. ALC ≥1000 cells/μL on day +23 was an independent predictive prognostic factors for better PFS (P = 0.003; Relative risk (RR) = 3.710; 95% Confidence interval (CI), 1.576–8.736) and showed tendency for prolonged OS (P = 0.065; RR=2.411; 95% CI, 0.946–6.142) (Table 1).In conclusion, ALC ≥1000 cells/mm3 recovery on day +23 was a good predictor for better survival in MM after APBSCT.
Table 1. Multivariate analysis for OS and PFS
| Variables . | . | OS . | . | . | PFS . | . |
|---|---|---|---|---|---|---|
| . | RR . | 95% CI . | P . | RR . | 95% CI . | P . |
| ANC, absolute neutrophil count; MNC, Mononuclear cell; ALC, absolute lymphocyte count | ||||||
| β2 microglobulin ≤ 3 vs > 3 mg/l | 3.497 | 1.32–9.25 | 0.012 | 2.215 | 0.962–5.101 | 0.062 |
| Serum albumin ≤ 3.7 vs > 3.7 g/dl | 0.337 | 0.139–0.816 | 0.016 | |||
| ANC≥ 500/mm³ recovery days≤ 11 vs > 11 | 2.677 | 1.044–6.864 | 0.040 | 1.360 | 0.616–3.001 | 0.447 |
| Infused MNC dose≤ 3.4 vs > 3.4 ×10^8/kg | 1.351 | 0.552–3.310 | 0.510 | |||
| Infused CD+34 dose≤ 6 vs > 6 ×10^6/kg | 0.609 | 0.209–1.779 | 0.365 | |||
| ALC≥ 1000/mm³ recovery days≤ 23 vs > 23 | 2.411 | 0.946–6.142 | 0.065 | 3.710 | 1.576–8.736 | 0.003 |
| Variables . | . | OS . | . | . | PFS . | . |
|---|---|---|---|---|---|---|
| . | RR . | 95% CI . | P . | RR . | 95% CI . | P . |
| ANC, absolute neutrophil count; MNC, Mononuclear cell; ALC, absolute lymphocyte count | ||||||
| β2 microglobulin ≤ 3 vs > 3 mg/l | 3.497 | 1.32–9.25 | 0.012 | 2.215 | 0.962–5.101 | 0.062 |
| Serum albumin ≤ 3.7 vs > 3.7 g/dl | 0.337 | 0.139–0.816 | 0.016 | |||
| ANC≥ 500/mm³ recovery days≤ 11 vs > 11 | 2.677 | 1.044–6.864 | 0.040 | 1.360 | 0.616–3.001 | 0.447 |
| Infused MNC dose≤ 3.4 vs > 3.4 ×10^8/kg | 1.351 | 0.552–3.310 | 0.510 | |||
| Infused CD+34 dose≤ 6 vs > 6 ×10^6/kg | 0.609 | 0.209–1.779 | 0.365 | |||
| ALC≥ 1000/mm³ recovery days≤ 23 vs > 23 | 2.411 | 0.946–6.142 | 0.065 | 3.710 | 1.576–8.736 | 0.003 |
Author notes
Corresponding author
